Last reviewed · How we verify
PRUCALOPRIDE
Prucalopride is a marketed drug primarily indicated for Chronic Idiopathic Constipation. Its key strength lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PRUCALOPRIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
- Chronic Idiopathic Constipation
Common side effects
- Headache
- Abdominal pain
- Nausea
- Diarrhea
- Abdominal distension
- Dizziness
- Vomiting
- Flatulence
- Fatigue
Serious adverse events
- Severe diarrhea
Key clinical trials
- Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway (PHASE4)
- Gastrointestinal Dysmotility on Aspiration Risk (PHASE4)
- A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy
- Prucalopride for Cognitive Functioning in Schizophrenia (NA)
- Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults (EARLY_PHASE1)
- Post-Marketing Study of Prucalopride Safety In Pregnancy
- Evolution of the Chicago Classification: Bridging Physiology and Mechanics (NA)
- A Study of Prucalopride in Breastfeeding Women With Constipation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |